Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Galmarini

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
British Journal of Cancer|July 20, 2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsM Serova, C M Galmarini, A Ghoul, et al.
British Journal of Cancer|September 15, 2001
Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicityC M Galmarini, N Falette, E Tabone, et al.
International Journal of Cancer|April 17, 2013
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)Michela Romano, Roberta Frapolli, Monique Zangarini, et al.
Oncotarget|March 31, 2016
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repairMichelle Lima, Hana Bouzid, Daniele G Soares, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 29, 1998
Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in FinlandJ F Dorgan, D Albanes, J Virtamo, et al.
Gynecologic Oncology|November 12, 2013
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trialBradley J Monk, Stanley B Kaye, Andrés Poveda, et al.
International Journal of Clinical and Experimental Pathology|January 19, 2013
Expression of XPG protein in human normal and tumor tissuesMiguel Aracil, Lisa M Dauffenbach, Marta Martínez Diez, et al.
British Journal of Cancer|July 7, 2017
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsCristina Belgiovine, Ezia Bello, Manuela Liguori, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|July 27, 2013
METHODOLOGICAL NOTE: Biomarkers (sex-hormone binding globulin (SHBG), bioavailable oestradiol, and bioavailable testosterone) and processing of blood samples in epidemiological studiesC M Fillmore, T R Fears, R N Hoover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxelCarlos M Galmarini, Isabelle Treilleux, Fatima Cardoso, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|July 20, 2007
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsM Serova, C M Galmarini, A Ghoul, et al.
British Journal of Cancer|September 15, 2001
Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicityC M Galmarini, N Falette, E Tabone, et al.
International Journal of Cancer|April 17, 2013
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104)Michela Romano, Roberta Frapolli, Monique Zangarini, et al.
Oncotarget|March 31, 2016
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repairMichelle Lima, Hana Bouzid, Daniele G Soares, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 29, 1998
Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in FinlandJ F Dorgan, D Albanes, J Virtamo, et al.
Gynecologic Oncology|November 12, 2013
Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trialBradley J Monk, Stanley B Kaye, Andrés Poveda, et al.
International Journal of Clinical and Experimental Pathology|January 19, 2013
Expression of XPG protein in human normal and tumor tissuesMiguel Aracil, Lisa M Dauffenbach, Marta Martínez Diez, et al.
British Journal of Cancer|July 7, 2017
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical modelsCristina Belgiovine, Ezia Bello, Manuela Liguori, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|July 27, 2013
METHODOLOGICAL NOTE: Biomarkers (sex-hormone binding globulin (SHBG), bioavailable oestradiol, and bioavailable testosterone) and processing of blood samples in epidemiological studiesC M Fillmore, T R Fears, R N Hoover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxelCarlos M Galmarini, Isabelle Treilleux, Fatima Cardoso, et al.
Pageof 13